Nanoparticles As Theranostic Vehicles in Prostate Cancer

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2019 Apr 30

PMID 31032309

Citations 1

Authors

Rafael Morales-Barrera

Cristina Suarez

Joaquin Mateo

Macarena Gonzalez

Joan Carles

Affiliations

Soon will be listed here.

Citing Articles

Biomolecule-functionalized nanoformulations for prostate cancer theranostics.

Pranav , Laskar P, Jaggi M, Chauhan S, Yallapu M J Adv Res. 2022; 51:197-217.

PMID: 36368516 PMC: 10491979. DOI: 10.1016/j.jare.2022.11.001.

References

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

Petrylak D, Tangen C, Hussain M, Lara Jr P, Jones J, Taplin M . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351(15):1513-20. DOI: 10.1056/NEJMoa041318. View

Kantoff P, Higano C, Shore N, Berger E, Small E, Penson D . Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5):411-22. DOI: 10.1056/NEJMoa1001294. View

de Bono J, Oudard S, Ozguroglu M, Hansen S, Machiels J, Kocak I . Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747):1147-54. DOI: 10.1016/S0140-6736(10)61389-X. View

de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005. PMC: 3471149. DOI: 10.1056/NEJMoa1014618. View

Sanna V, Sechi M . Nanoparticle therapeutics for prostate cancer treatment. Nanomedicine. 2012; 8 Suppl 1:S31-6. DOI: 10.1016/j.nano.2012.05.009. View

Scher H, Fizazi K, Saad F, Taplin M, Sternberg C, Miller K . Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13):1187-97. DOI: 10.1056/NEJMoa1207506. View

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

10.

Tinzl M, Chen B, Chen S, Semenas J, Abrahamsson P, Dizeyi N . Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancer. PLoS One. 2013; 8(11):e79573. PMC: 3832643. DOI: 10.1371/journal.pone.0079573. View

11.

Goldkorn A, Ely B, Quinn D, Tangen C, Fink L, Xu T . Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32(11):1136-42. PMC: 3970171. DOI: 10.1200/JCO.2013.51.7417. View

12.

Beer T, Armstrong A, Rathkopf D, Loriot Y, Sternberg C, Higano C . Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371(5):424-33. PMC: 4418931. DOI: 10.1056/NEJMoa1405095. View

13.

Sweeney C, Chen Y, Carducci M, Liu G, Jarrard D, Eisenberger M . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015; 373(8):737-46. PMC: 4562797. DOI: 10.1056/NEJMoa1503747. View

14.

James N, Sydes M, Clarke N, Mason M, Dearnaley D, Spears M . Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387(10024):1163-77. PMC: 4800035. DOI: 10.1016/S0140-6736(15)01037-5. View

15.

Von Hoff D, Mita M, Ramanathan R, Weiss G, Mita A, LoRusso P . Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016; 22(13):3157-63. DOI: 10.1158/1078-0432.CCR-15-2548. View

16.

Vogelzang N, Fizazi K, Burke J, de Wit R, Bellmunt J, Hutson T . Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016; 71(2):168-171. DOI: 10.1016/j.eururo.2016.07.051. View

17.

Seitz A, Rauscher I, Haller B, Kronke M, Luther S, Heck M . Preliminary results on response assessment using Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2017; 45(4):602-612. DOI: 10.1007/s00259-017-3887-x. View

18.

Schmidkonz C, Cordes M, Schmidt D, Bauerle T, Goetz T, Beck M . Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018; 45(11):1862-1872. DOI: 10.1007/s00259-018-4042-z. View

19.

Autio K, Dreicer R, Anderson J, Garcia J, Alva A, Hart L . Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2018; 4(10):1344-1351. PMC: 6233779. DOI: 10.1001/jamaoncol.2018.2168. View

20.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View